Board of Directors

DANIEL KAZADO
Daniel Kazado is a Senior Advisor to Melini Capital, a family owned private and public equity firm investing internationally in several industries. Melini Capital has been an early and significant investor in Immune Pharmaceuticals. Daniel built his own management consulting firm over 15 years to 25 professionals advising boards of directors and senior management in multiple industries, and in 2002 sold the company to Altran Technologies, a global engineering and management consulting group with revenues of over 1 billion. Daniel earned a bachelor’s degree in Business Administration and a master’s degree in Management from Lyon University in France.

 

CAMERON DURRANT, MD, LEAD INDEPENENT DIRECTOR AND CHAIRMAN OF THE COMPENSATION COMMITTEE
Cameron Durrant is a pharmaceutical and biotech executive and entrepreneur. He trained and practiced medicine in Wales and Australia, before embarking on a pharmaceuticals career, initially with Merck and GSK in the UK, where he held sales, marketing and business development roles. He subsequently held staff and line international and US domestic responsibility for businesses at Pharmacia Corporation (until its acquisition by Pfizer) and Johnson and Johnson.  He has been CEO/Chairman/CFO for four companies, two of which were public, one of which he founded and took public. He has been involved in five exits and raised over $50MM in investment funding.  He has launched 20 brands, nationally, regionally and globally, including five which sold >$1Bn annually and one >$3Bn annually; three brands were nominated for Prix Galien awards. He was an Ernst + Young ‘Entrepreneur Of The Year’ national finalist, and named in the annual ‘100 Most Inspiring Leaders in Pharma’ published by PharmaVoice on 3 separate occasions. Most recently, Cameron served as a corporate officer of Hi-Tech Pharmacal (recently sold to Akorn) and CEO of the ECR division (subsequently divested by Akorn to Valeant). Cameron earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, and his DipCH from the Melbourne Academy, Australia and his Master of Business Administration from Henley Management College, Oxford, UK. He is currently on the board of two private medical device companies and a founding board member of a private nanotech/oncology company.    

 

ELLIOT MAZA, CHAIR OF THE AUDIT COMMITTEE
Elliot Maza is Chairman, Chief Executive Officer and CFO at Intellect Neurosciences Inc.  Previously, Elliot was Chief Executive Officer and CFO at Biozone Pharmaceuticals, Inc. and Chief Financial Officer of Emisphere Technologies Inc. Elliot has been a Partner, Transaction Advisory Services, at Ernst & Young, LLP. He began his professional career as an Attorney at Sullivan and Cromwell in New York and then in Investment banking as Vice President of Structured Finance in the Fixed Income divisions of Goldman Sachs & Co., J.P. Morgan Securities, Inc. and BT Securities Corporation where he developed and marketed structured finance and derivative based transactions. Elliot has served on numerous Boards of Directors for OTC and NASDAQ traded companies, including positions as Chairman of the Audit Committee. He is a registered attorney and a licensed C.P.A. (inactive) in the states of New York and New Jersey. He received a B.A. in Accounting from Touro College in New York and a J.D. from the University of Pennsylvania Law School.

 

JEFF PALEY, MD, INDEPENDENT DIRECTOR
Dr. Jeff Paley has been an Active Clinician and Consultant in the healthcare industry for the past 19 years, during which time he  has consulted for over 30 analysts and portfolio managers in the biotechnology, pharmaceutical, specialty pharmaceutical and medical technology arenas, reviewing the clinical, preclinical and regulatory pedigrees of numerous therapeutics and devices. Dr. Paley has also consulted  for several biotechnology and specialty pharmaceutical companies, most notably in the areas of clinical development and business development and he has engineered transactions worth over $600 MM. Dr. Paley founded Access Medical Associates in 2003, after spending five years on the full-time academic faculty of Weill Cornell Medical College, where he served as a Director of Clinical Research at the Cornell Internal Medicine Associates. At Weill Cornell, Dr. Paley was a Principal or Co-Principal Investigator on several studies of diabetes, hypertension, and cholesterol disorders, including the landmark ACCORD study of intensive hyperglycemia, hypertension and hyperlipidemia management. He has served as a Director of Kellbenx and  Retrophin and currently serves as a Director of Kalytera, Avenue Therapeutics and Remote Radiology Inc., Dr. Paley trained at Harvard Medical School and completed a residency in Internal Medicine at Massachusetts General Hospital.

 

JOHN NECZESNY, MEMBER OF AUDIT COMMITTEE AND COMPENSATION COMMITTEE AND CHAIR OF TRANSACTION COMMITTEE
Mr. Neczesny brings over 27 years of investment banking and corporate experience to this role.  Mr. Neczesny has been a Managing Director at Oberon Securities, LLC, a boutique investment bank, since 2012, where he advises on and executes M&A and financing transactions principally for healthcare companies.  Previously, he was Vice President, Corporate Development at Par Pharmaceutical Companies from 2009 to 2011.  From 1998 to 2008, Mr. Neczesny was an investment banker at Bear Stearns & Co. Inc. in the Healthcare group, where he rose to Managing Director and was involved in numerous M&A and capital markets transactions for pharmaceutical, biotechnology and medical technology companies. Mr. Neczesny earned an MBA in Finance from New York University Stern School of Business and a Bachelor of Science degree in Chemistry from the University of Delaware.

 

DANIEL TEPER, CHIEF EXECUTIVE OFFICER

Dr. DANIEL TEPER, CHIEF EXECUTIVE OFFICER

Dr. Daniel Teper is the founder and CEO of IMMUNE Pharmaceuticals. He was the Managing Director for North America at Bionest Partners, a global Strategy Consulting firm advising pharmaceutical and public biotechnology companies and previously a New York based Partner at ISO Healthcare Consulting (now part of Deloitte Monitor). Daniel started his career at Novartis Global Headquarters in Basel and then in the United States where he had growing responsibilities in sales, marketing and new product development. He held senior executive positions in Europe, first at GSK as Head of Commercial Operations for Glaxo France and then as President and President of Laboratoires Delagrange through the acquisition by Synthelabo (now part of Sanofi). He then became Global President HAVAS Health, a leading marketing and communication group, where he helped launch multiple industry blockbusters. Daniel was a cofounder of Novagali (NYSE Euronext: NOVA), which was acquired by Japan’s Santen. Daniel holds a Doctor of Pharmacy degree (PharmD) from Paris XI University and an MBA from INSEAD.